Literature DB >> 16985999

Therapeutic strategies for localized prostate cancer.

J H Lynch, J T Batuello, E D Crawford, L G Gomella, J Kaufman, D P Petrylak, A B Joel.   

Abstract

Prostate-specific antigen determinations for prostate cancer screening have led to a dramatic increase in the number of men who are diagnosed with organ-confined and therefore potentially curable prostate cancer. Advances in predicting outcomes with artificial neural networks may help to recommend one therapy over another. Less invasive forms of treatment, such as high-intensity focused ultrasound, may ultimately give patients additional options for treatment. Furthermore, attempts to better define the role of both neoadjuvant hormonal therapy and chemotherapy may give higher-risk patients better outcomes than with current treatments. These advances as well as continued research will likely lead to a day when more and more men with organ-confined disease will be cured.

Entities:  

Year:  2001        PMID: 16985999      PMCID: PMC1476072     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  48 in total

Review 1.  Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma.

Authors:  H Ragde; A A Elgamal; P B Snow; J Brandt; A A Bartolucci; B S Nadir; L J Korb
Journal:  Cancer       Date:  1998-09-01       Impact factor: 6.860

2.  Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial.

Authors:  L G Gomella; S N Liberman; S G Mulholland; R O Petersen; T Hyslop; B W Corn
Journal:  Urology       Date:  1996-06       Impact factor: 2.649

3.  Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group.

Authors:  S L Goldenberg; L H Klotz; J Srigley; M A Jewett; D Mador; Y Fradet; J Barkin; J Chin; J M Paquin; M J Bullock; S Laplante
Journal:  J Urol       Date:  1996-09       Impact factor: 7.450

Review 4.  Neoadjuvant hormone therapy: the Canadian trials.

Authors:  L Klotz; M Gleave; S L Goldenberg
Journal:  Mol Urol       Date:  2000

5.  Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer.

Authors:  W P Witjes; C C Schulman; F M Debruyne
Journal:  Urology       Date:  1997-03       Impact factor: 2.649

6.  Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer.

Authors:  M T Macfarlane; A Abi-Aad; A Stein; J Danella; A Belldegrun; J B deKernion
Journal:  J Urol       Date:  1993-07       Impact factor: 7.450

7.  Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.

Authors:  M S Soloway; R Sharifi; Z Wajsman; D McLeod; D P Wood; A Puras-Baez
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

Review 8.  Estrogens in the treatment of prostate cancer.

Authors:  R L Cox; E D Crawford
Journal:  J Urol       Date:  1995-12       Impact factor: 7.450

Review 9.  Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer.

Authors:  W R Fair; A G Aprikian; D Cohen; P Sogani; V Reuter
Journal:  Clin Invest Med       Date:  1993-12       Impact factor: 0.825

10.  Sequelae of radical prostatectomy.

Authors:  M Jønler; E M Messing; P R Rhodes; R C Bruskewitz
Journal:  Br J Urol       Date:  1994-09
View more
  3 in total

1.  BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype.

Authors:  Crystal N Marconett; Travis J Morgenstern; Adrianna K San Roman; Shyam N Sundar; Ankur K Singhal; Gary L Firestone
Journal:  Cancer Biol Ther       Date:  2010-08-20       Impact factor: 4.742

2.  Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression.

Authors:  Jamin A Willoughby; Shyam N Sundar; Mark Cheung; Antony S Tin; Jaime Modiano; Gary L Firestone
Journal:  J Biol Chem       Date:  2008-11-17       Impact factor: 5.157

3.  Sexual rehabilitation after localized prostate cancer: current interventions and future directions.

Authors:  David M Latini; Stacey L Hart; David W Coon; Sara J Knight
Journal:  Cancer J       Date:  2009 Jan-Feb       Impact factor: 3.360

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.